These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date Terminated 2007-004866-42 An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer... bad-data
Not reported Terminated 2008-000803-26 A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma 2012-10-02 due-trials
Completed, but no date 2008-007798-18 An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Gastr... bad-data
Not reported 2008-007974-39 Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimi... 2015-08-14 due-trials
Completed, but no date Terminated 2009-014725-16 Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal canc... bad-data
Ongoing 2009-017731-17 An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type not-yet-due
Not reported 2010-020606-15 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer 2015-05-27 due-trials
Not reported 2010-022938-85 Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer 2016-03-01 due-trials
Completed, but no date 2010-024111-13 Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy bad-data
Not reported 2011-001024-38 Randomisierte Phase II Studie zum Vergleich der Therapie Vinorelbin in Kombination mit dem mTOR-Inhibitor Everolimus vs. Vinorelbin Monotherapie in der Zweitlinienbehandlung von Patientinnen mit metas... 2016-10-31 due-trials
Completed, but no date 2011-001507-13 Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable... bad-data
Completed, but no date 2012-004550-28 EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3... bad-data
Ongoing 2012-005422-30 Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab ... not-yet-due
Other 2013-002742-37 Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer not-yet-due
Completed, report not yet due 2013-004796-12 Prospective Randomized Multicenter Phase II Trial to 2020-02-19 not-yet-due
Completed, but no date Terminated 2013-005545-37 A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet) bad-data
Ongoing 2013-005559-34 Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) not-yet-due
Completed, but no date Terminated 2014-001983-36 Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patients w... bad-data
Ongoing 2014-004086-24 Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Ge... not-yet-due
Not reported Terminated 2014-005595-28 Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. 2017-03-16 due-trials
Other 2015-001123-22 A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung C... not-yet-due
Other 2015-001478-16 Rivaroxaban in the treatment of venous thrombembolism (VTE) in cancer patients – a randomized phase III Study not-yet-due
Ongoing 2015-002773-38 mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial not-yet-due
Ongoing 2015-005741-31 Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC not-yet-due
Ongoing 2016-000399-28 A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitinib ... not-yet-due
Ongoing 2016-001331-12 A randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with head and neck cancers not-yet-due
Other 2016-002170-13 A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months ... not-yet-due
Ongoing 2016-002307-26 A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma not-yet-due
Ongoing 2016-002467-34 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial not-yet-due
Ongoing 2016-003709-33 A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies not-yet-due
Ongoing 2016-003963-20 Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC not-yet-due
Ongoing 2016-004434-26 Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer – The phase II AVETUX-CRC trial. not-yet-due
Ongoing 2016-004750-15 A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. not-yet-due
Ongoing 2016-004857-33 A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma not-yet-due
Ongoing 2016-005147-17 Second-line therapy with Nal-IRI after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy not-yet-due
Ongoing 2017-000105-20 Neoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer not-yet-due
Ongoing 2017-000624-10 Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTEGA ... not-yet-due
Ongoing 2017-001538-25 A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladd... not-yet-due
Ongoing 2017-002056-86 A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer not-yet-due
Ongoing 2017-003349-14 A randomized phase II study on the optimization of immunotherapy in squamous carcinoma of the head and neck (OPTIM) not-yet-due
Ongoing 2017-003553-42 A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) not-yet-due
Ongoing 2019-001707-21 Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide not-yet-due